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ABSTRACT Chronic Pseudomonas aeruginosa lung infection is characterized by the
presence of endobronchial antibiotic-tolerant bioﬁlm, which is subject to strong oxy-
gen (O2) depletion due to the activity of surrounding polymorphonuclear leukocytes.
The exact mechanisms affecting the antibiotic susceptibility of bioﬁlms remain un-
clear, but accumulating evidence suggests that the efﬁcacy of several bactericidal
antibiotics is enhanced by stimulation of aerobic respiration of pathogens, while lack
of O2 increases their tolerance. In fact, the bactericidal effect of several antibiotics
depends on active aerobic metabolism activity and the endogenous formation of re-
active O2 radicals (ROS). In this study, we aimed to apply hyperbaric oxygen treat-
ment (HBOT) to sensitize anoxic P. aeruginosa agarose bioﬁlms established to mimic
situations with intense O2 consumption by the host response in the cystic ﬁbrosis
(CF) lung. Application of HBOT resulted in enhanced bactericidal activity of cipro-
ﬂoxacin at clinically relevant durations and was accompanied by indications of re-
stored aerobic respiration, involvement of endogenous lethal oxidative stress, and
increased bacterial growth. The ﬁndings highlight that oxygenation by HBOT im-
proves the bactericidal activity of ciproﬂoxacin on P. aeruginosa bioﬁlm and suggest
that bacterial bioﬁlms are sensitized to antibiotics by supplying hyperbaric O2.
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Chronic pulmonary infection with Pseudomonas aeruginosa in cystic ﬁbrosis (CF)patients is the ﬁrst bioﬁlm infection described in humans (1). In CF patients, chronic
lung infection with P. aeruginosa constitutes the major cause of increased morbidity
and mortality (2). Therefore, the dramatically increased tolerance of P. aeruginosa
bioﬁlms to antibiotics is a critical challenge for improving antibiotic treatment of
chronic lung infections in CF patients (3). Increased tolerance of P. aeruginosa bioﬁlms
to antibiotics is multifactorial (4) and may to some extent depend on restriction of
molecular oxygen (O2) (5, 6), which is distributed at low levels, reaching anoxia in parts
of the endobronchial secretions of chronically infected CF patients (7–9). Since O2 is a
prerequisite for aerobic respiration, shortage of O2 may decelerate aerobic respiration,
leading to increased tolerance to several antibiotics (10–12). This enhanced tolerance
possibly relies on decreased expression of antibiotic targets and antibiotic uptake (13)
as well as reduced endogenous lethal oxidative stress in response to downstream
events resulting from interaction between drugs and targets (11, 12). Accordingly, we
have previously shown that reoxygenation of O2-depleted P. aeruginosa bioﬁlms using
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hyperbaric oxygen treatment (HBOT) increases the susceptibility to ciproﬂoxacin. In
that study the O2 was removed by bacterial aerobic respiration (14). However, this may
be in contrast to the consumption of O2 in the endobronchial secretions of CF patients,
in which the vast majority of O2 is consumed by the polymorphonuclear leukocytes
(PMNs) for production of reactive O2 species (ROS) and nitric oxide (NO), whereas only
a minute part of O2 is consumed by aerobic respiration (8, 15). In fact, ongoing
anaerobic respiration and low in vivo growth rates of P. aeruginosa bioﬁlms (16) and of
several other bacterial pathogens (17–19) suggest limited bacterial aerobic respiration
(20). Therefore, in order to mimic situations in CF lungs where intense O2 consumption
by activated PMNs prevents engagement of bacterial aerobic respiration we have
grown bacterial bioﬁlm without O2 prior to antibiotic treatment and HBOT. Using this
approach, we aimed to examine if absent aerobic respiration may be restored by HBOT
for clinically relevant durations, leading to increased bactericidal effect of ciproﬂoxacin.
RESULTS
Effect of HBOT on P. aeruginosa bioﬁlm during ciproﬂoxacin treatment. Signif-
icantly less PAO1 bacteria survived 90 min of treatment with ciproﬂoxacin when HBOT
was applied (P  0.0001, n  13 to 19) (Fig. 1, left panel). The maximum enhancement
of bacterial killing by HBOT exceeded 2 log units when supplemented with 0.5 mg ·
liter1 of ciproﬂoxacin, indicating that P. aeruginosa bioﬁlm exposed to HBOT can be
treated with lower ciproﬂoxacin concentrations than controls.
It is striking that the potentiation of ciproﬂoxacin is stronger after 90 min of HBOT
than for 2 h of HBOT as previously reported (14). However, the present model has been
developed to better represent the in vivo microenvironment where P. aeruginosa is
deprived of O2 due to intense O2 depletion by the surrounding PMNs creating anoxia
(8). Furthermore, the depth of the agarose-embedded bioﬁlm has been decreased in
order for O2 to penetrate through large parts of the entire bioﬁlm within 90 min.
In P. aeruginosa a major part of the detoxiﬁcation of ROS is contributed by catalase
enzymes encoded by the katA gene (21, 22). Accordingly, the increased susceptibility
to antibiotics in mutants with defective katA expression, as well as the enhanced tolerance
to antibiotics in mutants with overexpression of catalase, is recognized as direct evidence
for a lethal effect of ROS generation during antibiotic treatment (12, 23, 24).
Therefore, we employed ΔkatA bioﬁlms to elucidate that ROS play a role in the
increased lethality of ciproﬂoxacin during HBOT. We found signiﬁcantly fewer ΔkatA
bacteria surviving 90 min of treatment with ciproﬂoxacin when HBOT was applied
compared with PAO1 bioﬁlms (P 0.0024, n 11 to 14), demonstrating a contribution
of oxidative stress to decreased bacterial survival (Fig. 1, right panel). This indicates that
FIG 1 Effect of simultaneous hyperbaric oxygen treatment (HBOT) on ciproﬂoxacin (0.25 to 2 mg · liter1) treatment of
anaerobic Pseudomonas aeruginosa bioﬁlms. (Left panel) Effect of anoxic (dotted line) and HBOT (solid line) conditions on
% surviving cells on agarose-embedded PAO1 bioﬁlms treated with ciproﬂoxacin (calculated as Δlog10 cell numbers) after
treatment for 90 min. Bars indicate the mean  standard error of the mean (n  13 to 19). (Right panel) Effect of
ciproﬂoxacin- and HBOT on 3-day-old agarose-embedded bioﬁlms of PAO1 (solid line) and katA (dotted line) (calculated
as Δlog10 cell numbers) after treatment for 90 min. Bars indicate the mean  standard error of the mean (n  11 to 14).
Signiﬁcant changes (P  0.05) by particular ciproﬂoxacin concentrations are indicated by asterisks (*). Statistical signiﬁ-
cance was evaluated by a two-way ANOVA test followed by Bonferroni’s multiple comparison tests.
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HBOT enabled aerobic respiration, allowing ciproﬂoxacin to induce formation of lethal
amounts of ROS (10). However, increased susceptibility of ΔkatA was only seen for the
higher concentrations of ciproﬂoxacin, suggesting that other antioxidative mechanisms
protect against the ROS produced during treatment with small amounts of ciproﬂoxa-
cin (10).
HBOT expands the bactericidal zone of ciproﬂoxacin treatment in P. aerugi-
nosa bioﬁlm. P. aeruginosa embedded in agarose that grows in discrete aggregates
was detected by confocal microscopy (Fig. 2) (25). Variations in aggregate size may
depend on whether initiation is from single or multiple cells. Aggregate diameter was
signiﬁcantly larger after 90 min of HBOT (100% O2, 280 kPa) than after anoxia (median
diameter [range]: 37 m (9 to 193 m) versus 23 m (7 to 66 m); P 0.0001, n 139)
estimated from live/dead staining of samples without ciproﬂoxacin treatment in the
upper 100 m of the agarose-embedded bioﬁlm. Aggregate volume was 4.2-fold
greater after 90 min of HBOT than after anoxia (median volume [m3]: 27 versus 6.4,
FIG 2 Lethality of ciproﬂoxacin-treated agarose-embedded Pseudomonas aeruginosa bioﬁlms during anoxic or
HBOT conditions. Visualization of representative 90-min ciproﬂoxacin and HBO-treated 3-day-old agarose-
embedded bioﬁlms of PAO1. Ciproﬂoxacin (0.25 to 2 mg liter1) treatment in anoxic agarose-embedded bioﬁlms
of PAO1 and in HBOT agarose-embedded bioﬁlms of PAO1. Samples were stained with Syto9 and propidium iodide
(PI) and obtained using a 63  1.4 numerical aperture (NA) Zeiss objective on a Zeiss 710 CLSM. Red denotes
bacterial membranes that are permeable to PI (dead bacteria); green bacteria are alive, since they have intact
membranes that are not permeable to PI. The bar in the photograph represents 500 m. (n  1).
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n  139), indicative of 4.2-fold more bacterial cells and an additional 2 divisions
compared to anoxic treatment. Furthermore, the propidium iodide (PI) experiments
were intended to conﬁrm the statistically signiﬁcant difference found with CFU count-
ing and to visualize the increased zone of bactericidal activity caused by HBOT during
ciproﬂoxacin treatment.
HBOT stimulates growth in P. aeruginosa bioﬁlm. Untreated PAO1 bioﬁlms em-
bedded in agarose were exposed to HBOT, with signiﬁcantly increased bacterial growth
demonstrated during the 90 min of incubation (P  0.0001, n  19). Compared with
growth under anoxic conditions, HBOT increased the density of PAO1 bioﬁlms without
antibiotic treatment, indicating that aerobic respiration increases bacterial growth (Fig.
3). In fact, 90 min of HBOT increased bacterial growth by 1⁄2 log compared to anaerobic
growth.
Distribution of O2 in P. aeruginosa bioﬁlm after HBOT. Vertical proﬁling of O2
concentration in the agarose-embedded bioﬁlm immediately after termination of 90
min of HBOT demonstrated O2 concentrations exceeding 1,000 mol · liter1 in the
media above the bioﬁlm surface (Fig. 4). Serial proﬁling revealed both rapid depletion
of O2 in the upper part of the bioﬁlm and O2 diffusion from the supernatant to the
normobaric atmosphere. However, within 20 min post HBOT, the zone of O2 depletion
inside the bioﬁlm was expanded and the O2 concentration of the supernatant de-
creased below atmospheric saturation, indicating that PAO1 was utilizing the available
O2 for aerobic respiration until O2 depletion in the bioﬁlm would necessitate conversion
to anaerobic respiration (Fig. 4).
O2 diffusion through the agarose gel alone was detected at agarose concentrations
from 0.125% to 2%. As expected (26), no signiﬁcant concentration dependence or
deviation from free diffusion was observed and accordingly the assumption was made
that O2 diffusion is not hindered by agarose or water in the bioﬁlm model (data not
shown).
Ciproﬂoxacin efﬁcacy is known to be linked to growth in view of the quinolone
target’s increased activity during DNA replication, both planktonically and in bioﬁlms
(27, 28). However, the inability to respire during aerobic respiration allows bacteria to
arrest growth in a manner that increases tolerance. This study shows that addition of
O2 sensitizes bacteria by stimulating growth in areas deprived of O2. It has been shown
previously that quinolones also have a bactericidal effect on ﬂow cell bioﬁlms but that
subpopulations remained tolerant to treatment. Similarly, our results on nonattached
bioﬁlm, reﬂecting a more accurate representation of chronic lung infection, show that
the bactericidal effect of ciproﬂoxacin improved with HBOT.
FIG 3 Hyperbaric oxygen treatment (HBOT) effect on bacterial growth in Pseudomonas aeruginosa
bioﬁlms. Effect of anoxic (circles) and HBOT (squares) conditions on bacterial growth (calculated as
Δlog10 cell numbers) after treatment for 90 min on agarose-embedded PAO1 bioﬁlms. Bars indicate
the mean  standard error of the mean (SEM) (n  19). Statistical signiﬁcance (P  0.05) was
evaluated by the Student’s t test.
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P. aeruginosa is clinically a very important respiratory pathogen that causes the most
severe complication of chronic lung infection in CF patients (2). Throughout the chronic
infection state, microbial bioﬁlms form as cell aggregates and become trapped in the
endobronchial mucus (29), with the host response creating chemical microenviron-
ments favoring bacterial physiology associated with tolerance against multiple antibi-
otics (20). Therefore, new treatment strategies are required to overcome these resilient
bacterial infections. HBOT has beneﬁcial effects on the treatment of a number of
infectious diseases, clinically, experimentally and in vitro (14, 20, 30), although whether
these can be expanded to bioﬁlm infections has not been extensively examined. The
present study utilized a model in which anoxic P. aeruginosa was embedded in an
agarose gel, trapping bacteria as aggregates throughout the gel in order to mimic
bioﬁlm infection in vivo (14, 30–32).
Few studies have shown that HBOT can be used as an adjuvant to ciproﬂoxacin
treatment on P. aeruginosa (33, 34) and to our knowledge our recently published
proof-of-concept study provided the ﬁrst demonstration that HBOT can enhance the
bactericidal activity of ciproﬂoxacin on bioﬁlms (14). In the present study, it has been
substantiated that bactericidal activity of ciproﬂoxacin is enhanced after only 90 min of
HBOT, representing a typical time frame used clinically for HBOT (35, 36). The Undersea
and Hyperbaric Medical Society recommends 90 to 120 min of HBOT per session (37).
Prior to HBOT, bacterial growth supported by aerobic respiration in the bioﬁlm model
was prevented by O2 exclusion while addition of NO3 enabled anaerobic respiration
by denitriﬁcation (38, 39). The rapid decrease from hyperoxia to hypoxia demonstrated
by serial measurements of O2 concentration proﬁles in the bioﬁlm immediately after
HBOT indicated engagement of aerobic bacterial respiration during HBOT, with this
metabolic shift likely explaining the observation of faster growth of PAO1 under HBOT
(40). Induction of increased metabolic activity by HBOT was further indicated by
increased SYTO9 ﬂuorescence intensity and bacterial aggregate size after HBOT, re-
sembling colonies in metabolically active zones in similar bioﬁlm models (25, 31).
Consequentially, activation of aerobic respiration by HBOT may contribute to the
enhanced bactericidal activity of ciproﬂoxacin by accelerating bacterial growth, as the
susceptibility to ciproﬂoxacin of P. aeruginosa bioﬁlm is correlated to growth rate (41).
In addition to a growth-related enhancement of ciproﬂoxacin treatment during
FIG 4 Optical microsensor measurement of the chemical gradient of O2 in ciproﬂoxacin-treated agarose-
embedded Pseudomonas aeruginosa bioﬁlm. Representative microproﬁling of the spatiotemporal dy-
namics of O2 in an agarose-embedded PAO1 bioﬁlm receiving HBOT for 90 min showing initial
accumulation of O2 in the media above the bioﬁlm surface and inside the bioﬁlm, followed by depletion.
The measurement of the O2 concentration proﬁle was initiated 4 min after termination of HBOT with
following proﬁling.
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HBOT, it was speculated that HBOT-induced reoxygenation of the bioﬁlm leads to
accumulation of cytotoxic ROS in response to ciproﬂoxacin. Induction of endogenous
production of cytotoxic ROS has been shown to contribute to the aerobic killing of
planktonic bacteria by several major classes of antibiotics (11, 12, 42), including aerobic
P. aeruginosa bioﬁlms (43), although the signiﬁcance of this has been challenged (11,
44, 45). However, increased susceptibility to antibiotics of mutants with deﬁcient
anti-oxidative defense is regarded as solid indication for a contribution of ROS to the
bactericidal effect of antibiotics (23). Thus, the increased killing of the ΔkatA mutant in
our study supports that endogenous generation of ROS can contribute to an enhanced
bactericidal effect of ciproﬂoxacin on bioﬁlm during adjuvant HBOT. Growth of ΔkatA was
not impaired with HBOT in the absence of ciproﬂoxacin treatment compared to the wild
type, indicating a lack of cytotoxic ROS generation by HBOT alone (data not shown).
Bioﬁlm infections are notoriously difﬁcult to eradicate with antimicrobial treatment,
as higher concentrations of antibiotics are frequently required for killing of bioﬁlms
compared to planktonic bacteria, with these concentrations being difﬁcult to match in
vivo (46). Our ﬁnding of signiﬁcantly increased bacterial killing during HBOT with only
2 MIC and 4 MIC of ciproﬂoxacin indicates that by using HBOT, P. aeruginosa
bioﬁlms can be effectively treated with lower ciproﬂoxacin levels that are attainable in
vivo.
Although still controversial, there is an increasing acceptance of the advantages of
HBOT, with a small number of studies focusing on the use of HBOT on bioﬁlm
infections, e.g., those associated with periodontal disease, osteomyelitis, and chronic
wounds (47–49). The effect of HBOT on bioﬁlm infections in the pulmonary system
remain largely unknown, although some studies have demonstrated the beneﬁcial
effect of HBOT in patients with acute abscesses and in experimental pulmonary
infection models with P. aeruginosa (50, 51). The feasibility of HBOT to sensitize
infectious bioﬁlm to antibiotics in patients is indicated by the fact of PAO1 being a
clinical isolate from a burn wound (52, 53). In addition, we have recently demonstrated
potentiation of tobramycin by HBOT on both in vitro and in vivo bioﬁlms of clinical
isolates of Staphylococcus aureus (54). However, a better understanding of the useful-
ness of HBOT in CF patients awaits further experiments with pathogens isolated
longitudinally, as well as with isolates with known resistance, including highly resistant
strains. The risk of development of barotrauma in the lungs, however, should raise
concerns when applying HBOT to patients with severely damaged lung tissue.
In summary, the ﬁndings of this study point to a new treatment strategy for bioﬁlm
infections by providing HBOT as an adjuvant to ciproﬂoxacin treatment, where the
increased availability of O2 leads to an increased susceptibility of P. aeruginosa bioﬁlms
to clinically relevant concentrations of antibiotic.
MATERIALS AND METHODS
Bacterial strains, media and antibiotics. Wild-type P. aeruginosa strain PAO1 was obtained from
the Pseudomonas Genetic Stock Center (http://www.pseudomonas.med.ecu.edu). Both the wild type and
a catalase-A-negative PAO1 (katA) mutant (22) were tested for susceptibility to the bactericidal
antibiotic ciproﬂoxacin (Bayer GmbH, Leverkusen, Germany). katA encodes the catalase enzyme respon-
sible for the major part of detoxiﬁcation of ROS in P. aeruginosa and accordingly the katA mutant was
chosen to demonstrate ROS contribution to ciproﬂoxacin activity. The MIC of PAO1 was 0.125 mg · liter1
as determined by Etest (bioMérieux, Ballerup, Denmark). Growth was in lysogeny broth (LB) (5 g · liter1
yeast extract [Oxoid, Basingstoke, UK], 10 g · liter1 tryptone [Oxoid], and 10 g · liter1 NaCl [Merck,
Rahway, NJ], pH 7.5), incubated overnight at 37°C and shaken at 150 rpm. For determination of bacterial
CFU counts, solid lactose agar plates (“Blue plates” based on a modiﬁed Conradi-Drigalski medium
containing 10 g · liter1 detergent, 1 g · liter1 Na2S2O3 · H2O, 0.1 g · liter1 bromothymolblue, 9 g · liter1
lactose, and 0.4 g · liter1 glucose, pH 8.0; Statens Serum Institut, Copenhagen, Denmark) were used to
select for Gram-negative bacteria. All plates were incubated overnight at 37°C.
Anaerobic growth. P. aeruginosa bioﬁlms were grown and treated under anoxic conditions in an
anaerobic growth chamber (Concept 400 Anaerobic Workstation, Ruskinn Technology Ltd., UK). The gas
atmosphere consisted of N2/H2/CO2 (ratio, 80:10:10). Anoxia was conﬁrmed with an optical O2 sensor
(HQ40d Portable multi meter; HACH Company, CO, USA) placed in the growth chamber. To remove traces
of O2, all media and chemical solutions applied for anaerobic work were equilibrated in the anaerobic
chamber 3 days prior to experiment.
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Susceptibility testing of mature bioﬁlms. Survival curves were assayed to investigate the effect of
HBOT on P. aeruginosa bioﬁlms treated with ciproﬂoxacin during 90 min. The optical density at 600 nm
(OD600) of overnight cultures of PAO1 or katA was adjusted to 0.4 before 100-fold dilution in LB medium
supplemented with 2% 2-hydroxyethyl-agarose (Sigma-Aldrich, Brøndby, Denmark) and 50 l was
loaded into 96-well microtiter plates (Nucleon Delta Surface; Thermo Fisher Scientiﬁc, Waltham, MA, USA)
to achieve a cell loading of 106 cells · ml1. The medium was supplemented with NaNO3 (1 mM)
(Sigma-Aldrich) to enable anaerobic respiration. The supernatant was replaced daily with 50 l of LB
medium supplemented with 1 mM NaNO3. Microtiter plates were covered with Paraﬁlm (Bemis, Neenah,
WI, USA) and lid and were incubated under anoxic conditions at 37°C for 3 days to establish mature
bioﬁlms. The density of mature untreated PAO1 and katA bioﬁlms was 7.7  106 CFU · ml1 and 7.6 
106 CFU · ml1, respectively, under anaerobic growth conditions. Treatment with ciproﬂoxacin was
initiated by replacing the supernatant with 50 l of a ciproﬂoxacin solution in LB medium (supplemented
with 1 mM NO3) in 2-fold dilutions from 0 to 2 mg · liter1. The plates were then further incubated for
90 min under anoxic or HBO conditions. At the termination of experiments, the supernatant was
discarded and the agarose-embedded PAO1 bioﬁlms were placed in 2.95 ml of phosphate-buffered
saline (PBS) (Substrate Department, Panum Institute, Copenhagen, Denmark) before resuspension for 15
to 20 s in a homogenizer (SilentCrusher M; Heidolph, Schwabach, Germany). Quantitative bacteriology
was performed by standard microbiological methods after incubation overnight at 37°C.
Hyperbaric oxygen treatment. Agarose-embedded bacteria were exposed to HBOT (100% O2) at a
pressure of 280 kPa (2.8 bar) at 37°C in a hyperbaric oxygen chamber (OXYCOM 250 ARC; Hypcom Oy,
Tampere, Finland). The HBOT sequence consisted of pressurization over 5 min to a pressure of 280 kPa.
The pressure was then applied for 90 min followed by 5 min of decompression. A constant temperature
at 37°C in the bioﬁlm samples was established by a circulating water system heater (FL300; Julabo,
Seelbach, Germany) placed underneath the microtiter plates in the hyperbaric oxygen chamber.
Sectioning and microscopy of agarose embedded bioﬁlm samples. Larger amounts of agarose-
embedded bioﬁlms were grown anaerobically with NO3 for 3 days in 24-well microtiter plates as
described above before subjection to similar treatment with ciproﬂoxacin and HBOT as the 96-well plate
bioﬁlm assays.
Microscopy and image analysis. With the use of a sterile 5-mm biopsy punch a cylindrical sample
was taken from the central part of the wells in the 24-well microtiter plates. The cylindrical gel samples
were cut into two halves, each with a ﬂat cut side. The cut samples were stained by applying 100 l of
a live/dead-stain mix of Syto9 (5 M; Molecular Probes, USA) and propidium iodide (PI) (20 M; Thermo
Fisher, USA) in MiliQ water. The stained samples were incubated in the dark for 15 min at room
temperature before being placed ﬂat-cut-side down on coverslips.
Samples were evaluated by confocal laser scanning microscopy (CLSM) on an LSM 880 Zeiss inverted
microscope running Zen 2012 (Zeiss, Germany). The samples were imaged at 100 magniﬁcation by
parallel tracks running 488-nm and 561-nm lasers exciting Syto9 and PI, respectively. Samples were
imaged with a 1  6-tile scan (1,416 m  7,091 m) and over a depth of 136 m in the z-direction.
Obtained z-stacks were rendered into three-dimensional (3D) projections and created in Imaris 8.3
(Bitplane, Switzerland).
Size and biomass of aggregates in CLSM image were measured with the use of Measure Pro
Expansion to Imaris 8.3. An isosurface was applied over the Syto9-stained biomass as well as over
biomass stained with PI. Isosurface particles larger than 100 m3 were consisted. All aggregates within
a depth of 100 m from the surface of the gel were measured and returned as a measured volume. The
radius of aggregates was calculated based on the assumption that aggregates were spherical. For
fractionation of live and dead cells the sum of biomass between Syto9 and PI was used as total biomass.
A fraction of both Syto9 and PI of the total biomass was then used as an estimate of live and dead cells.
Oxygen measurements. A 3-day-old untreated bioﬁlm in a 24-well microtiter plate was treated for
90 min with HBOT. Within 1 min of ending the experiment the microtiter plate was positioned on a
heated metal rack kept at 37°C and vertical microproﬁles of O2 concentration were recorded using a
computer-controlled micromanipulator (Pyro Science GmbH, Germany) equipped with a ﬁber-optic O2
microsensor (50 m tip diameter; Pyro Science GmbH, Germany) that was connected to a ﬁber-optic O2
meter (FireSting2; Pyro Science GmbH, Germany). The microsensor was calibrated according to the
manufacturer’s recommendations (air saturated and O2-free water). As the sample was kept at 37°C, this
temperature was set as the measurement temperature in the software. The microsensor was positioned
manually at the base of the bioﬁlm sample and proﬁle measurements were taken by moving the sensor
in vertical steps of 100 m through the bioﬁlm sample. Positioning and data acquisition were controlled
by dedicated software (Proﬁx version 4.51; Pyro Science).
Oxygen diffusion (control). Diffusion of oxygen in gels without cells was compared between
agarose concentrations of 0.125% to 2% with an NaCl concentration of 0.9 g · liter1. The gels were
placed in test tubes of 65 mm height and an inner diameter of 12 mm and left to congeal. Heights of
the agarose gels ranged from 21 to 41 mm. A total of 100 l saline water (0.9 g · liter1) was then added
on top of the gel to avoid drying and the tubes were sealed with Paraﬁlm. The test tubes were placed
in an anaerobic chamber (Concept 400; Baker Ruskinn) at 37°C for at least 8 days to deoxygenate. The
tip of the ﬁber-optic O2 micro sensor (OXR50-UHS; Pyroscience) was then positioned at 6 mm depth and
the oxygen level was recorded under normoxic conditions as the gel reoxygenated.
Statistical methods. Statistical signiﬁcance was evaluated by ordinary one- or two-way analysis of
variance (ANOVA) followed by Dunnett’s or Bonferroni’s multiple-comparison test, respectively, and by
Student’s t test. A P value of 0.05 was considered statistically signiﬁcant. Data from at least 3
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independent experiments were compared. Tests were performed with GraphPad Prism 6.1 (GraphPad
Software Inc., La Jolla, CA) and Microsoft Excel (Microsoft Corp., Redmond, WA).
ACKNOWLEDGMENTS
We are indebted to senior hyperbaric supervisor Michael Bering Sifakis for assisting
us with chamber support and maintenance.
This work was supported by grants from UC-CARE (University of Copenhagen Center
for Antimicrobial Research) through grant 50061804231-F16 to Mette Kolpen, the
Human Frontiers Science Program through grant RGY0081/2012, and the Lundbeck
Foundation through grant R105-A9791 to Thomas Bjarnsholt and Kasper N. Kragh, as
well as the Danish Council for Independent Research Natural Sciences (FNU) through
grant DFF-1323-00065B to Michael Kühl and Technology and Production Sciences (FTP)
through grant DFF–4184-00515 to Michael Kühl, Peter Østrup Jensen, and Klaus Koren.
The funders had no role in experimental design, data analysis and interpretation, or
the decision to submit the work for publication.
REFERENCES
1. Høiby N, Bjarnsholt T, Moser C, Jensen PØ, Kolpen M, Qvist T, Aanaes K,
Pressler T, Skov M, Ciofu O. 2017. Diagnosis of bioﬁlm infections in cystic
ﬁbrosis patients. APMIS 125:339–343. https://doi.org/10.1111/apm
.12689.
2. Høiby N, Ciofu O, Bjarnsholt T. 2010. Pseudomonas aeruginosa bioﬁlms in
cystic ﬁbrosis. Future Microbiol 5:1663–1674. https://doi.org/10.2217/
fmb.10.125.
3. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic
resistance of bacterial bioﬁlms. Int J Antimicrob Agents 35:322–332.
https://doi.org/10.1016/j.ijantimicag.2009.12.011.
4. Ciofu O, Rojo-Molinero E, Macia MD, Oliver A. 2017. Antibiotic treatment
of bioﬁlm infections. APMIS 125:304–319. https://doi.org/10.1111/apm
.12673.
5. Walters MC, III, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. 2003.
Contributions of antibiotic penetration, oxygen limitation, and low met-
abolic activity to tolerance of Pseudomonas aeruginosa bioﬁlms to cip-
roﬂoxacin and tobramycin. Antimicrob Agents Chemother 47:317–323.
https://doi.org/10.1128/AAC.47.1.317-323.2003.
6. Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS. 2004.
Oxygen limitation contributes to antibiotic tolerance of Pseudomonas
aeruginosa in bioﬁlms. Antimicrob Agents Chemother 48:2659–2664.
https://doi.org/10.1128/AAC.48.7.2659-2664.2004.
7. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P,
Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S,
Boucher RC, Döring G. 2002. Effects of reduced mucus oxygen concen-
tration in airway Pseudomonas infections of cystic ﬁbrosis patients. J Clin
Invest 109:317–325. https://doi.org/10.1172/JCI0213870.
8. Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van Gennip
M, Ciofu O, Mandsberg L, Kharazmi A, Dõring G, Givskov M, Høiby N,
Jensen PØ. 2010. Polymorphonuclear leucocytes consume oxygen in
sputum from chronic Pseudomonas aeruginosa pneumonia in cystic
ﬁbrosis. Thorax 65:57–62. https://doi.org/10.1136/thx.2009.114512.
9. Cowley ES, Kopf SH, LaRiviere A, Ziebis W, Newman DK. 2015. Pediatric
cystic ﬁbrosis sputum can be chemically dynamic, anoxic, and extremely
reduced due to hydrogen sulﬁde formation. mBio 6:e00767. https://doi
.org/10.1128/mBio.00767-15.
10. Lobritz MA, Belenky P, Porter CB, Gutierrez A, Yang JH, Schwarz EG,
Dwyer DJ, Khalil AS, Collins JJ. 2015. Antibiotic efﬁcacy is linked to
bacterial cellular respiration. Proc Natl Acad Sci U S A 112:8173–8180.
https://doi.org/10.1073/pnas.1509743112.
11. Brochmann RP, Toft A, Ciofu O, Briales A, Kolpen M, Hempel C, Bjarnsholt
T, Høiby N, Jensen PØ. 2014. Bactericidal effect of colistin on planktonic
Pseudomonas aeruginosa is independent of hydroxyl radical formation.
Int J Antimicrob Agents 43:140 –147. https://doi.org/10.1016/j
.ijantimicag.2013.10.015.
12. Dwyer DJ, Belenky PA, Yang JH, MacDonald IC, Martell JD, Takahashi N,
Chan CT, Lobritz MA, Braff D, Schwarz EG, Ye JD, Pati M, Vercruysse M,
Ralifo PS, Allison KR, Khalil AS, Ting AY, Walker GC, Collins JJ. 2014.
Antibiotics induce redox-related physiological alterations as part of their
lethality. Proc Natl Acad Sci U S A 111:E2100–E2109. https://doi.org/10
.1073/pnas.1401876111.
13. Van Acker H, Coenye T. 2017. The role of reactive oxygen species in
antibiotic-mediated killing of bacteria. Trends Microbiol 25:456–466.
https://doi.org/10.1016/j.tim.2016.12.008.
14. Kolpen M, Mousavi N, Sams T, Bjarnsholt T, Ciofu O, Moser C, Kühl M,
Høiby N, Jensen PØ. 2016. Reinforcement of the bactericidal effect of
ciproﬂoxacin on Pseudomonas aeruginosa bioﬁlm by hyperbaric oxygen
treatment. Int J Antimicrob Agents 47:163–167. https://doi.org/10.1016/
j.ijantimicag.2015.12.005.
15. Kolpen M, Bjarnsholt T, Moser C, Hansen CR, Rickelt LF, Kühl M, Hempel
C, Pressler T, Høiby N, Jensen PØ. 2014. Nitric oxide production by
polymorphonuclear leucocytes in infected cystic ﬁbrosis sputum con-
sumes oxygen. Clin Exp Immunol 177:310–319. https://doi.org/10.1111/
cei.12318.
16. Kragh KN, Alhede M, Jensen PØ, Moser C, Scheike T, Jacobsen CS, Seier
Poulsen S, Eickhardt-Sørensen SR, Trøstrup H, Christoffersen L, Hougen
HP, Rickelt LF, Kühl M, Høiby N, Bjarnsholt T. 2014. Polymorphonuclear
leukocytes restrict growth of Pseudomonas aeruginosa in the lungs of
cystic ﬁbrosis patients. Infect Immun 82:4477–4486. https://doi.org/10
.1128/IAI.01969-14.
17. Kolpen M, Kragh KN, Bjarnsholt T, Line L, Hansen CR, Dalbøge CS,
Hansen N, Kühl M, Høiby N, Jensen PØ. 2015. Denitriﬁcation by cystic
ﬁbrosis pathogens – Stenotrophomonas maltophilia is dormant in spu-
tum. Int J Med Microbiol 305:1–10. https://doi.org/10.1016/j.ijmm.2014
.07.002.
18. Kopf SH, Sessions AL, Cowley ES, Reyes C, Van Sambeek L, Hu Y, Orphan
VJ, Kato R, Newman DK. 2016. Trace incorporation of heavy water reveals
slow and heterogeneous pathogen growth rates in cystic ﬁbrosis spu-
tum. Proc Natl Acad Sci U S A 113:E110–E116. https://doi.org/10.1073/
pnas.1512057112.
19. DePas WH, Starwalt-Lee R, Van Sambeek L, Ravindra Kumar S, Gradinaru
V, Newman DK. 2016. Exposing the three-dimensional biogeography
and metabolic states of pathogens in cystic ﬁbrosis sputum via hydrogel
embedding, clearing, and rRNA labeling. mBio 7:e00796-16. https://doi
.org/10.1128/mBio.00796-16.
20. Jensen PØ, Kolpen M, Kragh KN, Kuhl M. 2017. Micro-environmental
characteristics and physiology of bioﬁlms in chronic infections of CF
patients are strongly affected by the host immune response. APMIS
125:276–288. https://doi.org/10.1111/apm.12668.
21. Hassett DJ, Cohen MS. 1989. Bacterial adaptation to oxidative stress:
implications for pathogenesis and interaction with phagocytic cells.
FASEB J 3:2574–2582.
22. Hassett DJ, Elkins JG, Ma JF, McDermott TR. 1999. Pseudomonas aerugi-
nosa bioﬁlm sensitivity to biocides: use of hydrogen peroxide as model
antimicrobial agent for examining resistance mechanisms. Methods En-
zymol 310:599–608. https://doi.org/10.1016/S0076-6879(99)10046-6.
23. Hassett DJ, Imlay JA. 2007. Bactericidal antibiotics and oxidative stress: a
radical proposal. ACS Chem Biol 2:708–710. https://doi.org/10.1021/
cb700232k.
24. Van Acker H, Sass A, Bazzini S, De Roy K, Udine C, Messiaen T, Riccardi G,
Boon N, Nelis HJ, Mahenthiralingam E, Coenye T. 2013. Bioﬁlm-grown
Burkholderia cepacia complex cells survive antibiotic treatment by avoid-
Kolpen et al. Antimicrobial Agents and Chemotherapy











ing production of reactive oxygen species. PLoS One 8:e58943. https://
doi.org/10.1371/journal.pone.0058943.
25. Sønderholm M, Kragh KN, Koren K, Jakobsen TH, Darch SE, Alhede M,
Jensen PØ, Whiteley M, Kühl M, Bjarnsholt T. 2017. Pseudomonas aerugi-
nosa aggregate formation in an alginate bead model system exhibits in
vivo-like characteristics. Appl Environ Microbiol 83:e00113-17. https://doi
.org/10.1128/AEM.00113-17.
26. Van der Meeren P, De Vleeschauwer D, Debergh P. 2001. Determination
of oxygen proﬁles in agar-based gelled in vitro plant tissue culture
media. Plant Cell Tissue Organ Cult 65:239–245. https://doi.org/10.1023/
A:1010698225362.
27. Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, McKay
G, Siehnel R, Schafhauser J, Wang Y, Britigan BE, Singh PK. 2011. Active
starvation responses mediate antibiotic tolerance in bioﬁlms and
nutrient-limited bacteria. Science 334:982–986. https://doi.org/10.1126/
science.1211037.
28. Spoering AL, Lewis K. 2001. Bioﬁlms and planktonic cells of Pseudomo-
nas aeruginosa have similar resistance to killing by antimicrobials. J
Bacteriol 183:6746–6751. https://doi.org/10.1128/JB.183.23.6746-6751
.2001.
29. Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen
CB, Pressler T, Givskov M, Høiby N. 2009. Pseudomonas aeruginosa
bioﬁlms in the respiratory tract of cystic ﬁbrosis patients. Pediatr Pul-
monol 44:547–558. https://doi.org/10.1002/ppul.21011.
30. Sjöberg F, Singer M. 2013. The medical use of oxygen: a time for critical
reappraisal. J Intern Med 274:505–528. https://doi.org/10.1111/joim
.12139.
31. Pabst B, Pitts B, Lauchnor E, Stewart PS. 2016. Gel-entrapped Staphylo-
coccus aureus bacteria as models of bioﬁlm infection exhibit growth in
dense aggregates, oxygen limitation, antibiotic tolerance, and hetero-
geneous gene expression. Antimicrob Agents Chemother 60:
6294–6301. https://doi.org/10.1128/AAC.01336-16.
32. Crone S, Garde C, Bjarnsholt T, Alhede M. 2015. A novel in vitro wound
bioﬁlm model used to evaluate low-frequency ultrasonic-assisted
wound debridement. J Wound Care 24:64–72. https://doi.org/10.12968/
jowc.2015.24.2.64.
33. Pakman LM. 1971. Inhibition of Pseudomonas aeruginosa by hyperbaric
oxygen. I. Sulfonamide activity enhancement and reversal. Infect Immun
4:479–487.
34. Lima FL, Joazeiro PP, Lancellotti M, de Hollanda LM, de Araujo Lima B,
Linares E, Augusto O, Brocchi M, Giorgio S. 2015. Effects of hyperbaric
oxygen on Pseudomonas aeruginosa susceptibility to imipenem and
macrophages. Future Microbiol 10:179–189. https://doi.org/10.2217/
fmb.14.111.
35. Neuman TS, Thom SR. 2008. Physiology and medicine of hyperbaric
oxygen therapy, 1st ed. Elsevier, Philadelphia, PA.
36. Brummelkamp WH, Hogendijk WT, Boerema I. 1961. Treatment of an-
aerobic infections (clostridial myositis) by drenching the tissues with
oxygen under high pressure. Surgery 49:299–302.
37. Gill AL, Bell CN. 2004. Hyperbaric oxygen: its uses, mechanisms of action
and outcomes. QJM 97:385–395. https://doi.org/10.1093/qjmed/hch074.
38. Kolpen M, Kühl M, Bjarnsholt T, Moser C, Hansen CR, Liengaard L,
Kharazmi A, Pressler T, Høiby N, Jensen PØ. 2014. Nitrous oxide produc-
tion in sputum from cystic ﬁbrosis patients with chronic Pseudomonas
aeruginosa lung infection. PLoS One 9:e84353. https://doi.org/10.1371/
journal.pone.0084353.
39. Line L, Alhede M, Kolpen M, Kühl M, Ciofu O, Bjarnsholt T, Moser C,
Toyofuku M, Nomura N, Høiby N, Jensen PØ. 2014. Physiological levels of
nitrate support anoxic growth by denitriﬁcation of Pseudomonas aerugi-
nosa at growth rates reported in cystic ﬁbrosis lungs and sputum. Front
Microbiol 5:554. https://doi.org/10.3389/fmicb.2014.00554.
40. Alvarez-Ortega C, Harwood CS. 2007. Responses of Pseudomonas aerugi-
nosa to low oxygen indicate that growth in the cystic ﬁbrosis lung is by
aerobic respiration. Mol Microbiol 65:153–165. https://doi.org/10.1111/j
.1365-2958.2007.05772.x.
41. Evans DJ, Allison DG, Brown MR, Gilbert P. 1991. Susceptibility of Pseu-
domonas aeruginosa and Escherichia coli bioﬁlms towards ciproﬂoxacin:
effect of speciﬁc growth rate. J Antimicrob Chemother 27:177–184.
https://doi.org/10.1093/jac/27.2.177.
42. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A
common mechanism of cellular death induced by bactericidal antibiot-
ics. Cell 130:797–810. https://doi.org/10.1016/j.cell.2007.06.049.
43. Jensen PØ, Briales A, Brochmann RP, Wang H, Kragh KN, Kolpen M,
Hempel C, Bjarnsholt T, Høiby N, Ciofu O. 2014. Formation of hydroxyl
radicals contributes to the bactericidal activity of ciproﬂoxacin against
Pseudomonas aeruginosa bioﬁlms. Pathog Dis 70:440–443. https://doi
.org/10.1111/2049-632X.12120.
44. Liu Y, Imlay JA. 2013. Cell death from antibiotics without the involve-
ment of reactive oxygen species. Science 339:1210–1213. https://doi
.org/10.1126/science.1232751.
45. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. 2013. Killing by bacte-
ricidal antibiotics does not depend on reactive oxygen species. Science
339:1213–1216. https://doi.org/10.1126/science.1232688.
46. Høiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G, Hall-
Stoodley L, Hola V, Imbert C, Kirketerp-Møller K, Lebeaux D, Oliver A,
Ullmann AJ, Williams C, Bioﬁlms ESGf Consulting External Expert Werner
Z. 2015. ESCMID guideline for the diagnosis and treatment of bioﬁlm
infections 2014. Clin Microbiol Infect 21(Suppl 1):S1–S25. https://doi.org/
10.1016/j.cmi.2014.10.024.
47. Coulson A, Peek A, Haugen D. 2016. Femoral vein cannulation in the
treatment of osteomyelitis. Wounds 28:194–199.
48. Fang RC, Galiano RD. 2009. Adjunctive therapies in the treatment of
osteomyelitis. Semin Plast Surg 23:141–147. https://doi.org/10.1055/s
-0029-1214166.
49. Signoretto C, Bianchi F, Burlacchini G, Canepari P. 2007. Microbiological
evaluation of the effects of hyperbaric oxygen on periodontal disease.
New Microbiol 30:431–437.
50. Luongo C, Imperatore F, Matera MG, Mangoni G, Marmo M, Baroni A,
Catalanotti P, Rossi F, Filippelli A. 1999. Effect of hyperbaric oxygen
therapy in experimental subcutaneous and pulmonary infections due to
Pseudomonas aeruginosa. Undersea Hyperb Med 26:21–25.
51. Marmo M, Contaldi G, Luongo C, Imperatore F, Tufano MA, Catalanotti P,
Baroni A, Mangoni G, Stefano S, Rossi F. 1996. [Effects of hyperbaric
oxygenation in skin and pulmonary infections caused by Pseudomonas
aeruginosa]. Minerva Anestesiol 62:281–287. (In Italian.)
52. Holloway BW. 1955. Genetic recombination in Pseudomonas aeruginosa.
J Gen Microbiol 13:572–581.
53. Holloway BW. 1975. Genetic organization of Pseudomonas, p 133–161. In
Clarke PHR, Richmond MH (ed), Genetics and biochemistry of Pseudomo-
nas. John Wiley and Sons Ltd., London, United Kingdom.
54. Lerche CJ, Christophersen LJ, Kolpen M, Nielsen PR, Trøstrup H, Thomsen
K, Hyldegaard O, Bundgaard H, Jensen PØ, Høiby N, Moser C. 2017.
Hyperbaric oxygen therapy augments tobramycin efﬁcacy in experimen-
tal Staphylococcus aureus endocarditis. Int J Antimicrob Agents 50:
406–412. https://doi.org/10.1016/j.ijantimicag.2017.04.025.
HBOT sensitizes P. aeruginosa bioﬁlm to ciproﬂoxacin Antimicrobial Agents and Chemotherapy




ctober 30, 2017 by KB, Københavns Universitetsbibliotek
http://aac.asm
.org/
D
ow
nloaded from
 
